ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically-targeted therapies for cardiovascular diseases,
today announced that it will make a presentation at the 27th
Annual Piper Jaffray Healthcare Conference.
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies
for cardiovascular diseases. The Company's lead product candidate,
GencaroTM (bucindolol hydrochloride), is an investigational,
pharmacologically unique beta-blocker and mild vasodilator being
developed for atrial fibrillation. ARCA has identified common genetic
variations that it believes predict individual patient response to
Gencaro, giving it the potential to be the first genetically-targeted
atrial fibrillation prevention treatment. ARCA has a collaboration with
Medtronic, Inc. for support of the GENETIC-AF trial. For more
information please visit www.arcabiopharma.com.
Safe Harbor Statement
This press release and the anticipated presentation contain
"forward-looking statements" for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. These
statements include, but are not limited to, statements regarding,
potential timing for patient enrollment in the GENETIC-AF trial,
potential timeline for GENETIC-AF trial activities, the sufficiency of
the Company’s capital to support its operations, the potential for
genetic variations to predict individual patient response to Gencaro,
Gencaro’s potential to treat atrial fibrillation, future treatment
options for patients with atrial fibrillation, and the potential for
Gencaro to be the first genetically-targeted atrial fibrillation
prevention treatment. Such statements are based on management's
current expectations and involve risks and uncertainties. Actual
results and performance could differ materially from those projected in
the forward-looking statements as a result of many factors, including,
without limitation, the risks and uncertainties associated with: the
Company's financial resources and whether they will be sufficient to
meet the Company's business objectives and operational requirements;
results of earlier clinical trials may not be confirmed in future
trials, the protection and market exclusivity provided by the Company’s
intellectual property; risks related to the drug discovery and the
regulatory approval process; and, the impact of competitive products and
technological changes. These and other factors are identified and
described in more detail in ARCA’s filings with the SEC, including
without limitation the Company’s annual report on Form 10-K for the year
ended December 31, 2014, and subsequent filings. The Company
disclaims any intent or obligation to update these forward-looking
statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151119005422/en/
Copyright Business Wire 2015